Trial Profile
A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Thrombopoietin (Primary)
- Indications Blood platelet disorders; Engraftment
- Focus Therapeutic Use
- 12 Nov 2015 New trial record
- 15 Jun 2014 Interim results presented at the 19th Congress of the European Haematology Association